

## PRESS RELEASE 14 June 2001

## ARTIMPLANT LAUNCHES REHABILITATION STUDY

The National Swedish Board of Health and Welfare and Gothenburg's committee on research ethics have approved an application from Artimplant to conduct a series of operations using Artimplant's augmentation device for anterior cruciate ligament reconstruction. The series of operations, which will comprise 10 patients, is intended to study whether the use of the augmentation device allows more active rehabilitation and a return to physical activity and training as early as 4 - 5 months after the operation.

The operations are scheduled to begin in August this year.

## **ARTIMPLANT**

Artimplant focuses on solving problems in the field of reconstructive surgery. Artimplant is active in research and development, manufacturing and marketing of degradable implants with the goal of recreating active lives for patients. The material the Company has developed is based on a new technology that opens up new markets in the field of orthopedic surgery and a variety of other specialized fields where there are significant medical needs. After many years of development work, Artimplant is now entering a marketing phase.

Among other things, Artimplant has developed and patented several different decomposable ligament implants now undergoing clinical trials. The Company is focusing on three high-priority areas for this degradable material: augmentation device for anterior cruciate ligament reconstruction, hand surgery, and augmentation sutures.

Artimplant is listed on the OM Stockholm Stock Exchange's O list and the Attract 40.

For further information, please contact:

Ulf Åkerblom

**Director Corporate Communications** 

Phone: 46 31 746 5600 Mobile: +46 709 67 59 99 E-mail: ulf.akerblom@artimplant.se

ulf.akerblom@artimplant.se

Anders Cedronius Chef Executive Officer Phone: +46 31 746 5689 Mobile: +46 706 42 27 45

E-mail: anders.cedronius@artimplant.se anders.cedronius@artimplant.se

www.artimplant.se